In contrast, excess IL‐6 causes inflammatory diseases; therefore, IL‐6 receptor antibody (Tocilizumab) has been used as therapeutic agent against Castleman disease and rheumatic diseases in the clinic (Rubbert‐Roth et al, 2018; Yoshizaki et al, 2018). The gene discussed is IL6; the disease is rheumatic disorder.